Dostarlimab combined with chemotherapy has shown potential in treating advanced or recurrent endometrial cancer, with reports of durable disease control. Regulatory approvals have been granted in the us and europe, expanding treatment options for this type of cancer. The exact scope and details of these approvals vary, but they appear to represent a significant development in endometrial cancer care.